Alemtuzumab or rituximab induction in ABO-incompatible kidney transplantation.
Recruiting
- Conditions
- ABO-incompatible kidney transplantation.Dutch:bloedgroep ABO-incompatible niertransplantatie.
- Registration Number
- NL-OMON28980
- Lead Sponsor
- investigator-drivenErasmus Medical Center Rotterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Recipients of an ABO-incompatible kidney transplant aged 18 years or older.
Exclusion Criteria
Recipients of an ABO-compatible kidney allograft.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -To compare the number of biopsy-proven acute rejections (BPAR) within three months after ABOi kidney transplantation in rituximab versus alemtuzumab treated patients.
- Secondary Outcome Measures
Name Time Method -To compare infectious complications after ABOi kidney transplantation in rituximab versus alemtuzumab treated patients.<br /><br>-T compare renal function one year after ABOi kidney transplantation in rituximab versus alemtuzumab treated patients.<br>